Puma Biotechnology (PBYI) Competitors $5.13 -0.09 (-1.72%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$5.10 -0.04 (-0.68%) As of 10/3/2025 07:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PBYI vs. ADMA, CTMX, TRDA, RAPP, SPRY, TNGX, PHAR, IMTX, UPB, and RLAYShould you be buying Puma Biotechnology stock or one of its competitors? The main competitors of Puma Biotechnology include ADMA Biologics (ADMA), CytomX Therapeutics (CTMX), Entrada Therapeutics (TRDA), Rapport Therapeutics (RAPP), ARS Pharmaceuticals (SPRY), Tango Therapeutics (TNGX), Pharming Group (PHAR), Immatics (IMTX), Upstream Bio (UPB), and Relay Therapeutics (RLAY). These companies are all part of the "pharmaceutical products" industry. Puma Biotechnology vs. Its Competitors ADMA Biologics CytomX Therapeutics Entrada Therapeutics Rapport Therapeutics ARS Pharmaceuticals Tango Therapeutics Pharming Group Immatics Upstream Bio Relay Therapeutics ADMA Biologics (NASDAQ:ADMA) and Puma Biotechnology (NASDAQ:PBYI) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, media sentiment, earnings, risk and analyst recommendations. Do analysts prefer ADMA or PBYI? ADMA Biologics presently has a consensus target price of $27.67, indicating a potential upside of 88.72%. Puma Biotechnology has a consensus target price of $7.00, indicating a potential upside of 36.45%. Given ADMA Biologics' stronger consensus rating and higher possible upside, analysts plainly believe ADMA Biologics is more favorable than Puma Biotechnology.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ADMA Biologics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 3.25Puma Biotechnology 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do institutionals & insiders believe in ADMA or PBYI? 75.7% of ADMA Biologics shares are owned by institutional investors. Comparatively, 61.3% of Puma Biotechnology shares are owned by institutional investors. 3.5% of ADMA Biologics shares are owned by insiders. Comparatively, 23.3% of Puma Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the media prefer ADMA or PBYI? In the previous week, ADMA Biologics had 2 more articles in the media than Puma Biotechnology. MarketBeat recorded 3 mentions for ADMA Biologics and 1 mentions for Puma Biotechnology. ADMA Biologics' average media sentiment score of 1.25 beat Puma Biotechnology's score of 0.00 indicating that ADMA Biologics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ADMA Biologics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Puma Biotechnology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is ADMA or PBYI more profitable? ADMA Biologics has a net margin of 44.06% compared to Puma Biotechnology's net margin of 20.38%. Puma Biotechnology's return on equity of 53.15% beat ADMA Biologics' return on equity.Company Net Margins Return on Equity Return on Assets ADMA Biologics44.06% 41.01% 28.47% Puma Biotechnology 20.38%53.15%23.51% Which has more volatility and risk, ADMA or PBYI? ADMA Biologics has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500. Comparatively, Puma Biotechnology has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500. Which has preferable valuation and earnings, ADMA or PBYI? ADMA Biologics has higher revenue and earnings than Puma Biotechnology. Puma Biotechnology is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioADMA Biologics$426.45M8.20$197.67M$0.8617.05Puma Biotechnology$230.50M1.12$30.28M$0.985.23 SummaryADMA Biologics beats Puma Biotechnology on 13 of the 17 factors compared between the two stocks. Get Puma Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for PBYI and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PBYI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PBYI vs. The Competition Export to ExcelMetricPuma BiotechnologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$258.40M$3.36B$6.13B$10.58BDividend YieldN/A2.28%5.65%4.69%P/E Ratio5.2322.2886.9626.71Price / Sales1.12458.33604.82131.77Price / Cash6.0247.8637.9061.31Price / Book2.739.9312.556.55Net Income$30.28M-$52.80M$3.31B$277.50M7 Day Performance5.99%5.22%4.28%2.42%1 Month Performance1.99%10.61%6.90%8.63%1 Year Performance93.58%25.03%70.54%31.60% Puma Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PBYIPuma Biotechnology3.5766 of 5 stars$5.13-1.7%$7.00+36.5%+93.6%$258.40M$230.50M5.23200ADMAADMA Biologics3.7679 of 5 stars$14.70-5.8%$27.67+88.2%-27.7%$3.73B$426.45M17.09530CTMXCytomX Therapeutics4.152 of 5 stars$3.23+11.4%$5.42+67.7%+187.0%$478.25M$138.10M5.77170TRDAEntrada Therapeutics3.1461 of 5 stars$5.84+0.7%$25.67+339.5%-64.9%$220.62M$79.48M-3.28110News CoveragePositive NewsRAPPRapport Therapeutics3.3059 of 5 stars$27.97+5.2%$35.33+26.3%+37.2%$970.48MN/A-11.19N/ASPRYARS Pharmaceuticals2.9126 of 5 stars$9.72-0.8%$33.17+241.2%-27.3%$968.50M$89.15M-19.8490Analyst RevisionTNGXTango Therapeutics2.3887 of 5 stars$8.44-1.1%$10.50+24.4%+11.2%$949.05M$24.30M-6.3590PHARPharming Group2.3322 of 5 stars$14.29+3.6%$30.00+109.9%+100.7%$944.82M$339.84M-109.92280News CoverageAnalyst DowngradeShort Interest ↑IMTXImmatics2.8052 of 5 stars$7.91+2.7%$15.00+89.6%-13.4%$935.94M$168.65M-12.17260UPBUpstream Bio2.0864 of 5 stars$17.34+0.5%$56.50+225.8%N/A$930.48M$2.37M0.0038RLAYRelay Therapeutics2.8384 of 5 stars$5.19+0.4%$16.50+217.9%-16.1%$891.37M$10.01M-2.66330 Related Companies and Tools Related Companies ADMA Biologics Competitors CytomX Therapeutics Competitors Entrada Therapeutics Competitors Rapport Therapeutics Competitors ARS Pharmaceuticals Competitors Tango Therapeutics Competitors Pharming Group Competitors Immatics Competitors Upstream Bio Competitors Relay Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PBYI) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top ad...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Puma Biotechnology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Puma Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PBYI Stock Alerts